Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma

Shane C. McAllister, Klaus Frueh, Ashlee Moses

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Kaposi's sarcoma (KS) is a multifocal angioproliferative disorder affecting the skin, mucosa and viscera of individuals infected with human herpesvirus-8 (HHV-8; also Kaposi's sarcoma-associated herpesvirus [KSHV]). KS is the most common neoplasm in AIDS patients; the clinical outcome of AIDS-KS is significantly improved by highly active antiretroviral therapy (HAART). However, in Africa, where the severest manifestations of KS occur, there is limited access to these and other effective but expensive drugs. Here we present a review of current efforts to identify novel therapeutic targets for the treatment of KS using functional genomics, with recommendations regarding the development of economically feasible treatments for use in Africa.

Original languageEnglish (US)
Pages (from-to)235-244
Number of pages10
JournalPharmacogenomics
Volume6
Issue number3
DOIs
StatePublished - Apr 2005

Fingerprint

Kaposi's Sarcoma
Genomics
Human Herpesvirus 8
Acquired Immunodeficiency Syndrome
Therapeutics
Viscera
Highly Active Antiretroviral Therapy
Mucous Membrane
Skin
Pharmaceutical Preparations
Neoplasms

Keywords

  • c-Kit
  • Gleevec®
  • HHV-8
  • HO-1
  • Kaposi's sarcoma
  • KSHV
  • Mesoporphyrins

ASJC Scopus subject areas

  • Pharmacology
  • Genetics(clinical)

Cite this

Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma. / McAllister, Shane C.; Frueh, Klaus; Moses, Ashlee.

In: Pharmacogenomics, Vol. 6, No. 3, 04.2005, p. 235-244.

Research output: Contribution to journalArticle

@article{2605c365f8964253a947e299c16ae01a,
title = "Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma",
abstract = "Kaposi's sarcoma (KS) is a multifocal angioproliferative disorder affecting the skin, mucosa and viscera of individuals infected with human herpesvirus-8 (HHV-8; also Kaposi's sarcoma-associated herpesvirus [KSHV]). KS is the most common neoplasm in AIDS patients; the clinical outcome of AIDS-KS is significantly improved by highly active antiretroviral therapy (HAART). However, in Africa, where the severest manifestations of KS occur, there is limited access to these and other effective but expensive drugs. Here we present a review of current efforts to identify novel therapeutic targets for the treatment of KS using functional genomics, with recommendations regarding the development of economically feasible treatments for use in Africa.",
keywords = "c-Kit, Gleevec{\circledR}, HHV-8, HO-1, Kaposi's sarcoma, KSHV, Mesoporphyrins",
author = "McAllister, {Shane C.} and Klaus Frueh and Ashlee Moses",
year = "2005",
month = "4",
doi = "10.1517/14622416.6.3.235",
language = "English (US)",
volume = "6",
pages = "235--244",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma

AU - McAllister, Shane C.

AU - Frueh, Klaus

AU - Moses, Ashlee

PY - 2005/4

Y1 - 2005/4

N2 - Kaposi's sarcoma (KS) is a multifocal angioproliferative disorder affecting the skin, mucosa and viscera of individuals infected with human herpesvirus-8 (HHV-8; also Kaposi's sarcoma-associated herpesvirus [KSHV]). KS is the most common neoplasm in AIDS patients; the clinical outcome of AIDS-KS is significantly improved by highly active antiretroviral therapy (HAART). However, in Africa, where the severest manifestations of KS occur, there is limited access to these and other effective but expensive drugs. Here we present a review of current efforts to identify novel therapeutic targets for the treatment of KS using functional genomics, with recommendations regarding the development of economically feasible treatments for use in Africa.

AB - Kaposi's sarcoma (KS) is a multifocal angioproliferative disorder affecting the skin, mucosa and viscera of individuals infected with human herpesvirus-8 (HHV-8; also Kaposi's sarcoma-associated herpesvirus [KSHV]). KS is the most common neoplasm in AIDS patients; the clinical outcome of AIDS-KS is significantly improved by highly active antiretroviral therapy (HAART). However, in Africa, where the severest manifestations of KS occur, there is limited access to these and other effective but expensive drugs. Here we present a review of current efforts to identify novel therapeutic targets for the treatment of KS using functional genomics, with recommendations regarding the development of economically feasible treatments for use in Africa.

KW - c-Kit

KW - Gleevec®

KW - HHV-8

KW - HO-1

KW - Kaposi's sarcoma

KW - KSHV

KW - Mesoporphyrins

UR - http://www.scopus.com/inward/record.url?scp=18044367899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044367899&partnerID=8YFLogxK

U2 - 10.1517/14622416.6.3.235

DO - 10.1517/14622416.6.3.235

M3 - Article

VL - 6

SP - 235

EP - 244

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 3

ER -